← Back to Search

Advanced MRI Techniques for Cardiovascular Disease

N/A
Recruiting
Led By Marcus Y Chen, M.D.
Research Sponsored by National Heart, Lung, and Blood Institute (NHLBI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects with known or suspected cardiovascular disease
Age greater than or equal to 7 years
Must not have
Important past or chronic medical illness such as major cardiovascular conditions like myocardial infarction, congenital heart disease, and known cardiomyopathy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up on going
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing new ways of imaging the heart and other organs using MRI. It will also look at the relationship between cardiovascular disease and other organ systems.

Who is the study for?
This trial is for people aged 7 and older, both healthy individuals and those with known or suspected cardiovascular disease. Participants must be able to lie still in an MRI scanner, follow instructions, provide informed consent (or have a guardian do so), and commit to the study procedures. Those previously exposed to gadolinium-based contrast agents or needing heart MRIs may also be of particular interest.
What is being tested?
The trial aims to develop new MRI methods for imaging the heart and other organs, describe cardiovascular diseases using these methods, examine the link between cardiovascular disease and risk factors affecting other organs, and detect any long-term brain deposits of gadolinium from previous MRIs. It involves up to 2-hour scans with potential monitoring of vital signs.
What are the potential side effects?
MRI is generally safe but can cause discomfort due to loud noises during scanning or claustrophobia inside the tube-like scanner. The contrast agent used may lead to allergic reactions in rare cases; however, participants will be screened for safety regarding this aspect.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a known or suspected heart condition.
Select...
I am 7 years old or older.
Select...
I do not have any known heart diseases.
Select...
I have a known or suspected serious illness besides heart disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of serious heart conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~on going
This trial's timeline: 3 weeks for screening, Varies for treatment, and on going for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assesment of Gad deposition in the brain
Evaluating the correlation
Technical development of MRI sequences
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
MRI
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI
2009
Completed Phase 2
~2810

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,918 Previous Clinical Trials
2,735,172 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)Lead Sponsor
3,935 Previous Clinical Trials
47,787,331 Total Patients Enrolled
Marcus Y Chen, M.D.Principal InvestigatorNational Heart, Lung, and Blood Institute (NHLBI)
6 Previous Clinical Trials
6,412 Total Patients Enrolled

Media Library

Cardiovascular Magnetic Resonance (CMR) Imaging Clinical Trial Eligibility Overview. Trial Name: NCT03581318 — N/A
Cardiovascular Physiology Research Study Groups: 1
Cardiovascular Physiology Clinical Trial 2023: Cardiovascular Magnetic Resonance (CMR) Imaging Highlights & Side Effects. Trial Name: NCT03581318 — N/A
Cardiovascular Magnetic Resonance (CMR) Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT03581318 — N/A
~1724 spots leftby Apr 2028